Hormone therapy requires follow-up after initial dosing. The first treatment plan provides a clinical starting point, but response can vary based on baseline hormone status, absorption, metabolism, symptoms, lifestyle factors, and route of administration.
Current clinical guidance reinforces the need for individualized monitoring. The Menopause Society notes that hormone therapy decisions should be individualized and periodically reevaluated based on benefits, risks, dose, duration, route, timing, and patient-specific factors.¹ The Endocrine Society also recommends evaluating men after testosterone therapy begins to assess response, adverse effects, and treatment adherence.²
Pellecome®, founded by Enrique G. Jacome, MD, FACOG, supports healthcare providers with evidence-informed BHRT solutions, advanced delivery methods, and clinical education designed to support long-term hormone management. Dr. Jacome is a board-certified OB-GYN whose background in minimally invasive surgery and hormone pellet insertion therapy helped shape Pellecome’s focus on precise delivery and provider training.
Initial Hormone Levels Are Only the Starting Point
Baseline labs help guide treatment planning, but they do not always predict how an individual will respond after therapy begins. Some patients notice symptom improvement quickly, while others need more time, follow-up testing, or additional evaluation.
Periodic lab review gives clinicians the opportunity to compare objective values with real-world symptom response. This is especially important when someone reports improvement in some areas but ongoing concerns in others, such as sleep, libido, fatigue, mood, or body composition.
When Providers Should Reassess Hormone Levels
The timing of follow-up depends on the individual, the therapy used, and the clinical goal. In general, post-treatment review may be useful when:
- Symptoms persist after initial treatment
- Symptoms improve and then begin returning
- New or unexpected side effects develop
- Energy, sleep, mood, libido, or recovery remain inconsistent
- Lab values need to be compared with symptom response
- Lifestyle changes, medications, or health conditions may be affecting outcomes
For pellet therapy, timing matters because hormone release occurs gradually. Medical teams may need to evaluate both symptom patterns and lab values within the context of the expected dosing interval, rather than relying on a single isolated measurement.
What Follow-Up Testing Helps Clarify
Follow-up testing can help clinicians determine whether hormone levels are moving toward the intended range, whether symptoms are improving, and whether other factors may be contributing to the clinical picture.
A structured review may also help identify:
- Dosing needs
- Changes in hormone metabolism
- Safety considerations
- Patient adherence to related recommendations
- The need for additional lab markers
- Lifestyle factors affecting treatment response
This process helps avoid overcorrecting, undertreating, or assuming that all ongoing symptoms are hormone-related. It also creates space for more specific patient education, especially when sleep, stress, nutrition, alcohol use, medications, or metabolic health may be influencing outcomes.
Supporting Long-Term Hormone Optimization
For clinicians offering BHRT, ongoing monitoring is essential to patient-centered care. Rechecking hormone levels after initial treatment can help refine protocols, improve communication, and support safer long-term management.
Pellecome® remains committed to equipping healthcare professionals with evidence-informed BHRT solutions, provider training, and high-quality products designed to support individualized care. A structured follow-up plan can help clinicians move beyond initial dosing and guide patients through long-term hormone management with greater clarity.
To learn more about Pellecome® and provider partnership opportunities, contact Pellecome® today.
- “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause [Internet]. 2022;29(7):767–94. Available from: http://dx.doi.org/10.1097/GME.0000000000002028
- Shalender Bhasin, Juan P Brito, Glenn R Cunningham, Frances J Hayes, Howard N Hodis, Alvin M Matsumoto, Peter J Snyder, Ronald S Swerdloff, Frederick C Wu, Maria A Yialamas, Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline, The Journal of Clinical Endocrinology & Metabolism, Volume 103, Issue 5, May 2018, Pages 1715–1744, https://doi.org/10.1210/jc.2018-00229
